Pharmaceuticals, Biotechnology and Life Sciences
Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the…
First patient dosed with UCARTCS1 in MELANI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Multiple Myeloma Patient screening ongoing with…
Cellectis has had first patient dosed with off-the-Shelf UCARTCS1 product candidate for relapsed/refractory multiple myeloma.
FDA approved IND for UCARTCS1 – first allogeneic CAR T-cell product candidate in multiple myeloma (MM) Ongoing construction of in-house…
“The SWIFF-CAR system does precisely that, representing a major breakthrough in our ongoing efforts to develop innovative applications to treat a range of diseases, including cancer and autoimmune diseases.”
Successful manufacturing and release of GMP vials of UCARTCS1 NEW YORK–(BUSINESS WIRE)–Regulatory News: Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS),…
Cellectis developed engineered GMCSF Knock-Out CAR T-cells through TALEN-mediated gene inactivation, which found to prevent secretion of pro-inflammatory cytokines by monocytes, without compromising CAR T-cell anti-tumor activity, thebiopharmaceutical company said Tuesday in a press release.
Cellectis, a French clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), on Tuesday announced a patent grant by the European Patent Office, for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
Cellectis S.A. and Calyxt, Inc. announced on Thursday the pricing of Calyxt’s initial public offering of 7,000,000 shares of its common stock at the initial public offering price of $8.00 per share.
U.S. Food and Drug Administration (FDA) has granted a French based biopharmaceutical company Cellectis an Investigational New Drug (IND) approval to start first phase clinical trial with UCART123 in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)